Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 26325033.
- Also identified by DOI 10.1172/JCI80006 and PMC identifier 4588310.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The generation of an inflammatory environment is favorable and often decisive for the growth of both primary tumors and metastases. Tumor cells either express membrane molecules or release tumor-derived soluble factors able to alter myelopoiesis. Tumor-reprogrammed myeloid cells not only create a tolerogenic environment by blocking T cell functions and proliferation, but also directly drive tumor growth by promoting cancer stemness, angiogenesis, stroma deposition, epithelial-to-mesenchymal transition, and metastasis formation. In this Review, we discuss the interplay between immunosuppressive and protumoral myeloid cells and detail their immune-regulatory mechanisms, the molecular pathways involved in their differentiation, as well as their potential role as prognostic and diagnostic biomarkers and prospective targets for innovative approaches to treat tumor-bearing hosts.
Medical subject headings
- Biomarkers, Tumor
- Cell Differentiation
- Epithelial-Mesenchymal Transition
- Immune Tolerance
- Macrophages
- Neoplasms